Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Pituitary substances, specifically pituitary gonadotropins such as follicle-stimulating hormone (FSH) and luteinizing hormone (LH), have a well-established scientific basis for use in the treatment of infertility. In the early 20th century, extracts from animal pituitary glands were among the first sources of gonadotropins used to induce ovulation in women with anovulatory infertility. Today, purified and recombinant forms of these hormones are routinely used in assisted reproductive technologies (ART), such as in vitro fertilization (IVF), and in the management of certain causes of male and female infertility.

Scientific evidence demonstrates that exogenous administration of FSH and LH can stimulate follicular development and ovulation in women with hypogonadotropic hypogonadism, polycystic ovary syndrome (PCOS), or unexplained infertility. In men, pituitary-derived gonadotropins can stimulate spermatogenesis in cases of hypogonadotropic hypogonadism. Numerous randomized controlled trials and clinical guidelines support the use of these hormones in fertility treatment protocols. While early pituitary extracts carried risks of contamination and disease transmission, modern preparations are highly purified or recombinant, offering improved safety profiles.

In summary, the use of pituitary-derived substances in infertility treatment is firmly grounded in scientific evidence, and their therapeutic efficacy is recognized in standard reproductive medicine.

More about pituitary substance
More about Infertility

Other ingredients used for Infertility

Other health conditions supported by pituitary substance

Products containing pituitary substance